99mTc-PSMA Uptake in Neurofibroma.

IF 9.6 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Nuclear Medicine Pub Date : 2025-03-03 DOI:10.1097/RLU.0000000000005797

Mohammad Hadi Samadi, Pegah Sahafi, Haniye Elahifard, Sima Davoodi, Emran Askari

引用次数: 0

Abstract

We present a 74-year-old man with a history of very high-risk prostate cancer (Gleason score: 5+4 in 11 of 14 cores) who was referred for initial staging with 99mTc-HYNIC-PSMA. The scan was reported as miT2m N2(REI, ROB) M1b(uni) M1c(skin?), PRIMARY score: 4, PSMA expression score: 1-3. We incidentally discovered increased uptake in the left skull region on whole-body images. Subsequent SPECT/CT imaging localized this uptake to a subcutaneous nodule in the scalp, which pathologic analysis confirmed to be a neurofibroma. Several lesions of neurological origin may exhibit significant PSMA avidity, which is reviewed here.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Nuclear Medicine 医学-核医学

CiteScore

2.90

自引率

31.10%

发文量

1113

审稿时长

2 months

期刊介绍： Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty. Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.